Download The Article
A 2023 Playbook for Emerging Biotech
A 2023 Playbook for Emerging Biotech
Winning at Your Drug Development Strategy: A Playbook for Emerging Biotechs
Early alignment with the regulatory authorities, identifying therapeutic experts, and identifying the right biomarkers can increase the chance of drug development success.
In a newly released whitepaper, a Playbook for Emerging Biotechs: Winning at Your Drug Development Strategy, Medpace experts share key strategies to overcome common biotech challenges – from a highly competitive environment, to funding challenges, to identifying the right biomarkers, and working with regulatory authorities.
An Integrated Partner for Biotech
trusted by biotech
There’s a reason 90% of our clients are small to mid-sized biotechs. While Medpace has grown over the last 30 years, the way we work with biotechs has not changed:
- We remain committed to being Trusted by Biotech®, which translates to keeping our culture and operating structure designed to accommodate efficient partnering, which is crucial for emerging biotechs with limited resources or experience
- Our purposeful, organic growth provides consistency in leadership, deep institution experience, and incomparable efficiencies, allowing your compound the attention it deserves
- We continue to expand our global reach and therapeutic expertise, providing resources to advance your medical therapeutic in any region.
Biotechs need a CRO that will give their program the attention it deserves. Medpace has prioritized biotechs for over three decades; we draw on our experience to create the best team and solution for you because at Medpace, we share the same commitment to your compound that you do.
